Portal de Periódicos da CAPES

Accuracy of contrast‐enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy

2001; Wiley; Volume: 96; Issue: 1 Linguagem: Inglês

10.1002/1097-0215(20010220)96

1097-0215

Sadako Akashi‐Tanaka, Takashi Fukutomi, Toru Watanabe, Noriyuki Katsumata, Takeshi Nanasawa, Kaneyuki Matsuo, Kunihisa Miyakawa, Hitoshi Tsuda,

MRI in cancer diagnosis

International Journal of CancerVolume 96, Issue 1 p. 66-73 Article Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy Sadako Akashi-Tanaka M.D., Corresponding Author Sadako Akashi-Tanaka M.D. [email protected] Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, JapanDepartment of Surgical Oncology, National Cancer Center Hospital, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. Phone: 3-3542-2511; Fax: 3-3545-3567Search for more papers by this authorTakashi Fukutomi M.D., Takashi Fukutomi M.D. Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorToru Watanabe M.D., Toru Watanabe M.D. Division of Medical Oncology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorNoriyuki Katsumata M.D., Noriyuki Katsumata M.D. Division of Medical Oncology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorTakeshi Nanasawa M.D., Takeshi Nanasawa M.D. Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorKaneyuki Matsuo M.D., Kaneyuki Matsuo M.D. Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorKunihisa Miyakawa M.D., Kunihisa Miyakawa M.D. Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorHitoshi Tsuda M.D., Hitoshi Tsuda M.D. Pathology Division, National Cancer Center Research Institute, Tokyo, JapanSearch for more papers by this author Sadako Akashi-Tanaka M.D., Corresponding Author Sadako Akashi-Tanaka M.D. [email protected] Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, JapanDepartment of Surgical Oncology, National Cancer Center Hospital, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. Phone: 3-3542-2511; Fax: 3-3545-3567Search for more papers by this authorTakashi Fukutomi M.D., Takashi Fukutomi M.D. Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorToru Watanabe M.D., Toru Watanabe M.D. Division of Medical Oncology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorNoriyuki Katsumata M.D., Noriyuki Katsumata M.D. Division of Medical Oncology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorTakeshi Nanasawa M.D., Takeshi Nanasawa M.D. Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorKaneyuki Matsuo M.D., Kaneyuki Matsuo M.D. Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorKunihisa Miyakawa M.D., Kunihisa Miyakawa M.D. Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, JapanSearch for more papers by this authorHitoshi Tsuda M.D., Hitoshi Tsuda M.D. Pathology Division, National Cancer Center Research Institute, Tokyo, JapanSearch for more papers by this author First published: 27 February 2001 https://doi.org/10.1002/1097-0215(20010220)96:1 3.0.CO;2-TCitations: 30Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Determination of the extent of residual disease after neoadjuvant chemotherapy is sometimes inaccurate by conventional diagnostic methods. The purpose of this study was to evaluate the accuracy of contrast-enhanced computed tomography (CE-CT) in depicting the extent of residual carcinomas. Fifty-seven patients with breast carcinomas of 3 cm diameter or more received neoadjuvant chemotherapy with four cycles of AT (doxorubicin and docetaxel). Before surgery, the patients underwent clinical examination, mammogram (MMG), ultrasonography (US), and CE-CT. Thirteen patients were not evaluated by CE-CT before surgery. Enhancement patterns on CE-CT were classified into multiple spots, tumor and spots, solid tumor type, and no enhancement. When all types of cancers were included in the analysis, clinical examination showed the best correlation with the pathology of the extent of residual carcinomas. However, except in invasive lobular carcinoma (ILC) and inflammatory breast carcinoma (IBC), CE-CT showed the best correlation (R⁁2 = 0.537). More than half of the residual microcalcifications on MMG after neoadjuvant chemotherapy suggested residual viable tumor. In conclusion, CE-CT is the most accurate noninvasive technique for identifying the extent of the residual carcinoma after neoadjuvant chemotherapy if cases of IBC and ILC are excluded. Int. J. Cancer (Radiat. Oncol. Invest.) 96, 66–73 (2001). © 2001 Wiley-Liss, Inc. REFERENCES 1Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A. Effect of preoperative chemotherapy on the outocome of women with operative breast cancer. J Clin Oncol 1998; 16: 2672–2685. 10.1200/JCO.1998.16.8.2672 CASPubMedWeb of Science®Google Scholar 2Dershaw DD, Drossman S, Liberman L, Abramson A. Assessment of response to therapy of primary breast cancer by mammography and physical examination. Cancer 1994; 75: 2093–2098. 10.1002/1097-0142(19950415)75:8 3.0.CO;2-2 PubMedWeb of Science®Google Scholar 3Segel M, Paulus DD, Hortobagyi GN. Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology 1988; 169: 49–54. 10.1148/radiology.169.1.3420282 PubMedWeb of Science®Google Scholar 4Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemothrapy for locally advanced breast carcinoma. Clin Cancer Res 1997; 3: 1565–1569. CASPubMedWeb of Science®Google Scholar 5Hortobagyi GN, Singletary SE, Strom EA. Treatment of locally advanced and inflammatory breast cancer. In: J Harris, ME Lippman, M Morrow, CK Osborne (eds). Diseases of the Breast, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p 647. Google Scholar 6Singletary S, McNeese M, Hortobagyi GN. Feasibility of breast-conservation chemotherapy for locally advanced breast carcinoma. Cancer 1992; 69: 2849–2852. 10.1002/1097-0142(19920601)69:11 3.0.CO;2-P PubMedWeb of Science®Google Scholar 7Akashi-Tanaka S, Fukutomi T, Miyakawa K, Tsuda H. Diagnostic value of enhanced computed tomography in the detection of the widely spreading intraductal component of breast cancer: case reports. Breast Cancer 1997; 4: 29–32. 10.1007/BF02967052 PubMedGoogle Scholar 8Akashi-Tanaka S, Fukutomi T, Miyakawa K, Uchiyama N, Tsuda H. Diagnostic value of contrast-enhanced computed tomography for diagnosing the intraductal component of breast cancer. Breast Cancer Res Treat 1998; 49: 79–86. 10.1023/A:1005986529910 CASPubMedWeb of Science®Google Scholar 9Healey EA, Osteen RT, Schnitt SJ, Gelman R, Stomper PC, Connolly JL, Harris JR. Can the clinical and mammographic findings at presentation predict the presence of an intensive intraductal component in early stage breast cancer. Int J Radiat Oncol Biol Phys 1989; 17: 1217–1221. 10.1016/0360-3016(89)90529-4 CASPubMedWeb of Science®Google Scholar 10Tsunoda HS, Ueno E, Tohno E, Akisada M. Echogram of ductal spreading of breast carcinoma. Jpn J Med Ultrasonics 1990; 17: 44–48 (in Japanese with English abstract). Google Scholar 11 The Japanese Breast Cancer Society. General Rules for Clinical and Pathological Recording of Breast Cancer. Tokyo: Kanehara; 1998. pp 69–72. Google Scholar 12Lluch A, Cervantes A, Pardo JD, Cervera V, Pallardo Y, Ferrando F, Juan O, Martinez-Agullo A, Azagra P, Lledo S. Assessment of primary tumor and axillary (AX) involvement in breast cancer after neoadjuvant chemotherapy. A comparison of clinical examination, mammography, ultrasonography and CT-scan. Proc Am Soc Clin Oncol 1995; 14: 135. Google Scholar 13Mumtaz H, Davidson T, Spitttle M, Tobias J, Craggs MAH, Cowley G, Taylor I. Breast surgery after neoadjuvant treatment. Is it necessary? Eur J Surg Oncol 1996; 22: 335–341. 10.1016/S0748-7983(96)90132-8 CASPubMedWeb of Science®Google Scholar 14Gilles R, Guinebretiere J-M, Toussaint C, Spielman M, Rietjens M, Petit J-Y, Contesso G, Masselot J, Vael D. Locally advanced breast cancer: Contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994; 191: 633–638. 10.1148/radiology.191.3.8184039 CASPubMedWeb of Science®Google Scholar 15Trecate G, Ceglia E, Stabile F, Tesoro-Tess JD, Mariani G, Zambetti M, Musumeci R. Locally advanced breast cancer treated with primary chemotherapy: comparison between magnetic resonance imaging and pathologic evaluation of residual disease. Tumori 1999; 85: 220–228. 10.1177/030089169908500402 CASPubMedWeb of Science®Google Scholar 16Tsuboi N, Ogawa Y, Inomata T, Yoshida D, Yoshida S, Moriki T, Kumon M. Changes in the findings of dynamic MRI by preoperative CAF chemotherapy for patients with breast cancer of stage II and III: pathologic correlation. Oncology 1999; 6: 727–732. CASWeb of Science®Google Scholar 17Adler DD, Wahl RL. New methods for imaging the breast: techniques, findings, and potential. Am J Radiol 1995; 164: 19–30. PubMedWeb of Science®Google Scholar 18Akashi-Tanaka S, Fukutomi T, Miyakawa K, Nanasawa T, Matsuo K, Hasegawa T, Tsuda H. Constrast-enhanced computed tomography diagnosing the intraductal component and small invasive foci of breast cancer. Breast Cancer (in press). Google Scholar 19Wahl R, Zasadny K, Helvie M, Hutchins G, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101–2111. 10.1200/JCO.1993.11.11.2101 PubMedWeb of Science®Google Scholar 20Buadu L, Murakami J, Murayama S, Hashiguchi N, Sakai S, Masuda K, Toyoashima S, Kuroki S, Ohno S. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996; 200: 639–649. 10.1148/radiology.200.3.8756909 CASPubMedWeb of Science®Google Scholar Citing Literature Volume96, Issue120 February 2001Pages 66-73 ReferencesRelatedInformation